Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buguzhi total glycosides capsules is a botanical drug candidate consisting of the total glycoside fraction extracted from *Psoralea corylifolia* L. (Fructus Psoraleae), a traditional Chinese medicine known as Buguzhi. Developed by the Jiangsu Province Academy of Traditional Chinese Medicine, the drug is intended for the treatment of primary osteoporosis. The extract contains various bioactive compounds, including phytoestrogens, which are thought to stimulate osteoblast differentiation and inhibit osteoclast activity, thereby improving bone mineral density. It is currently undergoing Phase I clinical evaluation in China to assess its safety, tolerability, and pharmacokinetic profile in healthy volunteers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Buguzhi total glycosides capsules.